The Use of Memantine for Prevention of Alzheimer's Disease

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

As the US population ages, the prevalence of dementia is increasing, and Alzheimer's Disease (AD) is the most prevalent one. Solving the Alzheimer's Disease (AD) epidemic is likely to require preventive therapy beginning many years before symptoms are expected to be evident in at-risk individuals. AD is caused by the dysfunction, loss of synapses, and eventual neuronal death, which may occur up to 25 years before clinical symptoms appear. This study, based off of pre-clinical data, seeks to assess whether it is feasible to use memantine hydrochloride for the prevention of Alzheimer's Disease.

Key facts

Study ID

NCT05063851

Run by

University of Virginia

People needed

32

Starts

2021-10-11

Expected to finish

2026-12-01

Last updated by the study team

2026-01-14

Who can join

Age: 50 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Be between the age of 50 and 65 years at time of informed consent.
• Have a positive family history for dementia (minimum of 1 first degree relative).
• Previously known or documented heterozygote or homozygote ApoE ε4 allele.
• Be able to read and write and must have adequate hearing and visual acuity to complete the psychometric tests.
• Be otherwise healthy for their age group or medically stable with or without medication on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening or at baseline.
• Have Montreal Cognitive Assessment (MOCA) score of 27 or above.
• Have a creatinine clearance (CrCl), estimated using the Cockcroft-Gault formula, greater or equal to 30 mL/minute.

You may not qualify if…

• A current clinical condition or requires a medication that raises the pH of their urine.
• Severe renal or hepatic impairment.
• Any other abnormality that could cause a possible cognitive deficit (including, but not limited to, vascular encephalopathy or large strokes).
• Contraindications for MRI (e.g., prostheses, implants, claustrophobia, pacemaker) or PET imaging.
• Neurodegenerative disorder known to cause neurocognitive decline
• Relevant history of or current neurological disease other than preclinical AD, which may make interpretation of possible new neurological signs or symptoms difficult.
• Clinically significant and active pulmonary, gastrointestinal, renal, hepatic, endocrine, or cardiovascular system disease
• Ongoing cancer treatment
• Clinically significant and active psychiatric disorder
• Use of an investigational medical device within 3 months before the planned start of study.
• Current participation in an interventional study with an investigational drug component.
• Major surgery (e.g., requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgery, or has major surgery planned during the time the subject is expected to participate in the study.
• Requires treatment with an AChE inhibitor or any of the following: acetazolamide, methazolamide, amantadine, ketamine, dextromethorphan.

Where it is running

• University of Virginia — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.